Skip to Content

Kanuma FDA Approval History

FDA Approved: Yes (First approved December 8, 2015)
Brand name: Kanuma
Generic name: sebelipase alfa
Dosage form: Injection
Company: Alexion Pharmaceuticals, Inc.
Treatment for: Lysosomal Acid Lipase Deficiency

Kanuma (sebelipase alfa) is an enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D).

Development Timeline for Kanuma

DateArticle
Dec  8, 2015ApprovalFDA Approves Kanuma (sebelipase alfa) for Lysosomal Acid Lipase Deficiency
Sep  6, 2015Alexion Receives Notification of PDUFA Date Extension for Kanuma (sebelipase alfa)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.